Post
The importance of finding a versatile, scalable CDMO in the softgel market
Finding the right contract development and manufacturing organisation (CDMO) isn’t easy. In a crowded pharmaceutical market, CDMOs must offer specialist …
The importance of AI in protecting hospitals from cyberattacks
Cyberattacks are especially dangerous when it comes to healthcare companies, as they collect and utilise sensitive patient data. For these organizations, …
Theolytics secures funds to advance oncolytic adenovirus therapy
UK-based biotechnology company Theolytics has concluded a funding round securing a total of £19m ($24.5m) to advance the development of …
Essential Pharma acquires Reminyl from Janssen Pharmaceutica
Speciality pharmaceutical group Essential Pharma has concluded the acquisition of Reminyl oral capsules from Johnson & Johnson company Janssen Pharmaceutica. The …
TC-110 by Adaptimmune Therapeutics for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval
TC-110 is under clinical development by Adaptimmune Therapeutics and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic …
B-Vaxx by Imugene for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval
B-Vaxx is under clinical development by Imugene and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Positive …
SLATE-001 by Gritstone Bio for Gastrointestinal Tumor: Likelihood of Approval
SLATE-001 is under clinical development by Gritstone Bio and currently in Phase I for Gastrointestinal Tumor. According to GlobalData, Phase …
SLATE-001 by Gritstone Bio for Metastatic Ovarian Cancer: Likelihood of Approval
SLATE-001 is under clinical development by Gritstone Bio and currently in Phase I for Metastatic Ovarian Cancer. According to GlobalData, …
SLATE-001 by Gritstone Bio for Metastatic Breast Cancer: Likelihood of Approval
SLATE-001 is under clinical development by Gritstone Bio and currently in Phase I for Metastatic Breast Cancer. According to GlobalData, …
Ftortiazinon by Gamaleya Federal Research Center of Epidemiology and Microbiology for Urinary Tract Infections: Likelihood of Approval
Ftortiazinon is under clinical development by Gamaleya Federal Research Center of Epidemiology and Microbiology and currently in Phase II for …
Rovadicitinib by Sino Biopharmaceutical for Hemophagocytic Lymphohistiocytosis: Likelihood of Approval
Rovadicitinib is under clinical development by Sino Biopharmaceutical and currently in Phase I for Hemophagocytic Lymphohistiocytosis. According to GlobalData, Phase …
Monlunabant by Inversago Pharma for Obesity: Likelihood of Approval
Monlunabant is under clinical development by Inversago Pharma and currently in Phase II for Obesity. According to GlobalData, Phase II …
Monlunabant by Inversago Pharma for Metabolic Syndrome: Likelihood of Approval
Monlunabant is under clinical development by Inversago Pharma and currently in Phase II for Metabolic Syndrome. According to GlobalData, Phase …
Supernitro by Attgeno for Pulmonary Embolism: Likelihood of Approval
Supernitro is under clinical development by Attgeno and currently in Phase I for Pulmonary Embolism. According to GlobalData, Phase I …
RiMO-401 by Coordination Pharmaceuticals for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
RiMO-401 is under clinical development by Coordination Pharmaceuticals and currently in Phase I for Head And Neck Squamous Cell Carcinoma …